We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+37.44%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.04B
AUM Growth
+$198M
Cap. Flow
+$14M
Cap. Flow %
1.35%
Top 10 Hldgs %
42.78%
Holding
150
New
56
Increased
28
Reduced
29
Closed
29

Top Buys

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$12.9M
2
LHCG
LHC Group LLC
LHCG
+$9.74M
3
CNMD icon
CONMED
CNMD
+$7.65M
4
LIVN icon
LivaNova
LIVN
+$7.59M
5
IMVT icon
Immunovant
IMVT
+$5.8M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.47M
2
XLRN
Acceleron Pharma
XLRN
+$5.43M
3
STAA icon
STAAR Surgical
STAA
+$5.36M
4
QDEL icon
QuidelOrtho
QDEL
+$5.09M
5
ADPT icon
Adaptive Biotechnologies
ADPT
+$4.68M

Sector Composition

Rank Sector Weight
1 Healthcare 38.45%
2 Industrials 1.39%
3 Energy 1.11%
4 Consumer Discretionary 0.31%
5 Consumer Staples 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BTAI icon
101
BioXcel Therapeutics
BTAI
$32.4M
$1.09M 0.1%
+1,281
New +$835K
INO icon
102
CALL
Inovio Pharmaceuticals
INO
$79.5M
$1.08M 0.1%
+3,333
New +$535K
AGTC
103
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.06M 0.1%
191,899
-15,459
-7% -$70.8K
RVNC
104
DELISTED
Revance Therapeutics, Inc.
RVNC
$999K 0.1%
+40,900
New +$807K
LEGN icon
105
Legend Biotech
LEGN
$3.98B
$872K 0.08%
+20,500
New +$801K
SVRA icon
106
Savara
SVRA
$1.17B
$868K 0.08%
348,768
+7,900
+2% +$19.2K
VSTM icon
107
Verastem
VSTM
$631M
$862K 0.08%
+41,782
New +$1.11M
ZYNE
108
CALL
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$806K 0.08%
+239,300
New +$1.13M
STSA
109
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$802K 0.08%
+27,872
New +$645K
TRIL
110
DELISTED
Trillium Therapeutics Inc.
TRIL
$799K 0.08%
98,787
+2,300
+2% +$14.2K
SRACU
111
DELISTED
Stable Road Acquisition Corp. Unit
SRACU
$748K 0.07%
74,070
– –
ZYME icon
112
Zymeworks
ZYME
$1.76B
$739K 0.07%
+20,500
New +$755K
EOLS icon
113
CALL
Evolus
EOLS
$541M
$694K 0.07%
131,000
+3,000
+2% +$13.8K
EOLS icon
114
PUT
Evolus
EOLS
$541M
$434K 0.04%
+81,900
New +$377K
SRRA
115
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$229K 0.02%
18,940
– –
TPST icon
116
CALL
Tempest Therapeutics
TPST
$19.2M
$225K 0.02%
656
– –
ATXS
117
DELISTED
Astria Therapeutics
ATXS
$119K 0.01%
3,085
+67
+2% +$2.39K
FPRX
118
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$68K 0.01%
+11,100
New +$45.7K
MAPSW
119
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
$25K ﹤0.01%
50,000
– –
ABEO icon
120
Abeona Therapeutics
ABEO
$421M
– –
-7,454
Closed -$391K
AMRN
121
PUT
Amarin Corp
AMRN
$300M
– –
-25,880
Closed -$2.07M
ATRC icon
122
CALL
AtriCure
ATRC
$2.19B
– –
-565,000
Closed -$19M
AUPH icon
123
Aurinia Pharmaceuticals
AUPH
$2.06B
– –
-98,913
Closed -$1.44M
AXSM icon
124
CALL
Axsome Therapeutics
AXSM
$11.3B
– –
-10,000
Closed -$588K
CRBP icon
125
Corbus Pharmaceuticals
CRBP
$184M
– –
-4,000
Closed -$808K
2 3 4
5
6

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q2 2020 Portfolio in Review

As of Q2 2020, Pura Vida Investments held 150 positions worth $1.04B, up 23% from $842M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Pura Vida Investments's Q2 2020 filing shows 56 new, 28 increased, 29 reduced and 29 closed positions. Its largest new stake was LHC Group LLC: 66,359 shares worth $11.6M. The largest sale was Regeneron Pharmaceuticals, an estimated $5.47M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 35% a quarter earlier, followed by Industrials and Energy.

  • Pura Vida Investments's largest Q2 2020 buy was LHC Group LLC: 66,359 shares worth $11.6M.
  • Pura Vida Investments added most to AtriCure in Q2 2020, an estimated $12.9M increase.
  • Pura Vida Investments's biggest Q2 2020 reduction was Acceleron Pharma, cutting an estimated $5.43M.
  • Pura Vida Investments fully exited Regeneron Pharmaceuticals in Q2 2020, selling an estimated $5.47M.
  • Pura Vida Investments's ten largest holdings make up 43% of its $1.04B portfolio in Q2 2020.
  • Pura Vida Investments opened 56 new positions and closed 29 in Q2 2020.
  • Pura Vida Investments's portfolio value rose 23% quarter-over-quarter to $1.04B.

Based on Pura Vida Investments's 13F filing for Q2 2020, filed 14 Aug 2020.